Transparency Market Research Report Added "Non-invasive Prenatal Testing Market" to its database.

Albany, NY -- (SBWire) -- 03/25/2016 --Non-invasive prenatal testing is progressively being adopted by pregnant women who are at a high risk for common fetal chromosomal aneuploidies, including Patau syndrome, Edwards syndrome, Turner syndrome, and Down syndrome. Non-invasiveness, safety, and accuracy are the key factors credited for the popularity of these tests across the globe.

In 2013, the global non-invasive prenatal testing market was valued at US$0.5 bn and is estimated to reach a value of US$2.4 bn by the end of 2022. The market is projected to exhibit a progressive 17.50% CAGR between 2014 and 2022.

Availability of Other Screening Tests to Inhibit Growth of NIPT Market

The growing prevalence of babies being born with Down syndrome, the growing demand for early and non-invasive fetal testing procedures, and rising average maternal age across the globe are some of the major factors expected to fuel the growth of the global NIPT market in the coming years. Moreover, realization of the potential offered by some of the developing countries in Asia Pacific is further estimated to drive the overall market in the next few years.

On the flip side, the availability of other screening and testing procedures, the limitations of NIPT, and regulatory and ethical hurdles are the factors hampering the growth of the global NIPT market.

The global market for non-invasive prenatal testing can be classified on the basis of test into NIFTY, Harmony, PrenaTest, VisibiliT, MaterniT21 PLUS, verifi, informaSeq, Panorama, and BambniTest. All these tests are based on detailed study of cell-free fetal DNA in the mother's blood.

In 2011, the first non-invasive prenatal test was introduced in the global market: MaterniT21 PLUS, which was used for the diagnosis of trisomy 21. In 2013, this test was the most widely accepted test in the overall market and held a 36.1% share in the global NIPT market. Nevertheless, in the near future, the number of MaterniT21 tests that are performed across the globe is estimated to decrease due to the introduction and commercialization of several other tests, including NIFTY, Panorama, and verify.

Request A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=374

North America Led Global Non-invasive Prenatal Testing Market due to Presence of Key Players in the U.S.

The global market for non-invasive prenatal testing can be divided on the basis of geography into Asia Pacific, Europe, North America, and Rest of the World. In 2013, North America dominated the overall market, holding a 58.8% share in terms of revenue and a 51% share in terms of volume in the global NIPT market. The rapid growth of this region can be attributed to the growing awareness regarding NIPT and the established presence of prominent players in the U.S. North America is followed by Europe, which is estimated to register substantial growth in the coming years owing to the rising penetration of U.S.-based test developers and growing acceptance of these tests.

On the other hand, India, China, Japan, and Australia are some of the promising markets in the Asia Pacific region expected to drive the global market. These countries have a large population of women favoring late pregnancy. The China NIPT market is led by local players such as Berry Genomics and BGI Diagnostics. Moreover, the CFDA approval for BambniTest is estimated to fuel the growth of the market in the next few years.

Some of the prominent players operating in the global market for non-invasive prenatal testing are LifeCodexx AG, BGI Diagnostics, Sequenom Inc., Natera Inc., LabCorp, Berry Genomics, Ariosa Diagnostics, and Illumina, Inc. (Verinata Health, Inc.).

Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/